Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560809 | 0.98 | BLM (0.37) | BLMPMP22HSD17B10 | |
| SCHEMBL17841938 | 0.98 | BLM (0.37) | BLMPMP22HSD17B10 | |
| SCHEMBL1903387 | 0.98 | BLM (0.37) | BLMPMP22HSD17B10 | |
| SCHEMBL21070958 | 0.87 | MEN1 (0.37) | — | |
| SCHEMBL17183915 | 0.85 | BLM (0.34) | BLMPMP22HSD17B10 | |
| Hydrochloric Acid SCHEMBL4699208 | 0.85 | HSD17B10 (0.36) | HSD17B10 | |
| SCHEMBL361520 | 0.83 | TSHR (0.39) | BLMPMP22HSD17B10 | |
| SCHEMBL3815296 | 0.83 | BLM (0.35) | BLMPMP22HSD17B10 | |
| SCHEMBL21997786 | 0.82 | — | — | |
| SCHEMBL21070941 | 0.81 | MEN1 (0.41) | BLMPMP22HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595318-B2 | — | — | 2026-04-07 | — | — | US | disclosed |
| US-20240316248-A1 | TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-09-26 | — | — | US | disclosed |
| EP-4406606-A2 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G | Bayer Pharma Aktiengesellschaft (DE) | 2024-07-31 | — | — | EP | disclosed |
| US-20240174772-A1 | NOVEL CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-30 | — | — | US | disclosed |
| US-11932708-B2 | Crosslinked alginic acid | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-19 | — | — | US | disclosed |
| EP-4268855-A1 | TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACID | Mochida Pharmaceutical Co., Ltd. (JP) | 2023-11-01 | — | — | EP | disclosed |
| US-20220409773-A1 | TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-3991792-A1 | TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACID | Mochida Pharmaceutical Co., Ltd. (JP) | 2022-05-04 | — | — | EP | disclosed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
| EP-3808783-A1 | NOVEL CROSSLINKED ALGINIC ACID | Mochida Pharmaceutical Co., Ltd. (JP) | 2021-04-21 | — | — | EP | disclosed |
| WO-2016207098-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-CD123-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016207103-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| US-9402914-B2 | Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides | SIRNA THERAPEUTICS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| WO-2016096610-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | WO | disclosed |
| US-20150165058-A1 | MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2015-06-18 | — | — | US | disclosed |
| US-20130280204-A1 | Polymer-Attached Inhibitors of Influenza Virus | NATIONAL INSTITUTES OF HEALTH | 2013-10-24 | — | — | US | disclosed |
| US-20030069445-A1 | Biological reagents and methods for determining the mechanism in the generation of beta-amyloid peptide | AUDIA JAMES E (US) | 2003-04-10 | — | — | US | disclosed |
| US-6486350-B1 | Biological reagents and methods for determining the mechanism in the generation of β-amyloid peptide | ELAN PHARMACEUTICALS INC. | 2002-11-26 | — | — | US | disclosed |
| EP-1131634-A2 | DETERMINING THE MECHANISM OF BETA-AMYLOID PEPTIDE GENERATION | Elan Pharmaceuticals, Inc. (US) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000019210-A2 | DETERMINING THE MECHANISM OF BETA-AMYLOID PEPTIDE GENERATION | ELAN PHARMACEUTICALS, INC. (US) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150165058-A1 | MEMBRANE LYTIC POLY(AMIDO AMINE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | PUF60, PHOSPHO1, PARG | BLM 708/4885PMP22 2225/4885HSD17B10 4462/4885 |
| US-20130280204-A1 | Polymer-Attached Inhibitors of Influenza Virus | PARG, PARN, SARS1 | BLM 1631/4885PMP22 3226/4885HSD17B10 4674/4885 |
| US-12595318-B2 | — | ALG1, ALG8, FUCA1 | BLM 3348/4885PMP22 4181/4885HSD17B10 3671/4885 |
| US-20030069445-A1 | Biological reagents and methods for determining the mechanism in the generation of beta-amyloid peptide | APP, IAPP, BACE1 | BLM 2071/4885PMP22 585/4885HSD17B10 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.